Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biotechnology company focused on NK cell therapies for autoimmune diseases and cancers, Artiva uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and risk factors.
Recent Form 8-K filings highlighted in the available data include current reports on quarterly financial results, initial safety and translational data for AlloNK (AB-101) in autoimmune disease, and corporate matters such as amendments to the 2024 Equity Incentive Plan and equity award exchanges for certain executives. Other 8-Ks reference FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis and summarize clinical findings from ongoing Phase 1 and 2 trials combining AlloNK with anti-CD20 monoclonal antibodies after cyclophosphamide and fludarabine conditioning.
Through this page, users can review Artiva’s periodic reports, including 10-Q and 10-K filings, to understand research and development expenses, cash, cash equivalents and investments, net losses, and other financial information the company reports. AI-generated summaries can highlight key sections related to AlloNK’s clinical development, the CAR-NK oncology pipeline, the strategic partnership with GC Cell for NK cell manufacturing technology, and the company’s stated risk factors.
Investors can also reference proxy materials and equity plan amendments to see how Artiva structures compensation and equity incentives, as illustrated by the amendment to the 2024 Equity Incentive Plan approved at the 2025 Annual Meeting. Form 4 insider transaction reports, when available, can be used to monitor equity activity by directors and officers. Real-time updates from EDGAR combined with AI explanations help make ARTV’s regulatory record more accessible to readers who want to understand the company’s clinical, financial and governance disclosures in detail.
Artiva Biotherapeutics granted its Chief Tech Operations Officer 107,156 restricted stock units (RSUs) of common stock on December 12, 2025 under its 2024 Equity Incentive Plan as part of an option exchange.
On the same date, the company cancelled employee stock options covering 77,519 and 9,119 shares at an exercise price of $5.01 and options for 20,519 shares at $13.47, in exchange for the new RSUs. After these transactions, the officer directly beneficially owns 185,339 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. reported that a senior officer (COO, CLO, Secretary and Compliance Officer) exchanged stock options for restricted stock units on December 12, 2025.
The officer received 84,877 restricted stock units granted under the company’s 2024 Equity Incentive Plan at a stated price of $0, bringing direct beneficial ownership to 232,925 shares of common stock.
As part of the same option exchange, the company cancelled employee stock options to buy 41,039, 9,119, 14,202 and 20,519 shares of common stock with exercise prices ranging from $5.01 to $13.47, all of which now show zero derivative securities beneficially owned.
Artiva Biotherapeutics, Inc. President and CEO, who also serves as a director, reported an equity compensation change effective December 12, 2025. The company cancelled several employee stock options listed in the filing, with exercise prices ranging from $5.01 to $13.47 per share, covering multiple grants that were scheduled to vest over multi-year periods.
In exchange for the cancelled options, the reporting person received 869,136 restricted stock units under the company’s 2024 Equity Incentive Plan, recorded at a price of $0 per unit. Following this option-for-RSU exchange, the reporting person beneficially owned 1,213,135 shares of the company’s common stock, held directly.
Artiva Biotherapeutics, Inc. implemented a one-time exchange program allowing a limited group of employees, including its President and CEO Fred Aslan and COO/CLO Jennifer Bush, to surrender underwater stock options for restricted stock units (RSUs) under the 2024 Equity Incentive Plan. The goal is to enhance retention and better align employee incentives with stockholders by replacing options with little current value.
Dr. Aslan surrendered options to purchase 869,136 shares of common stock and Ms. Bush surrendered options to purchase 84,877 shares. In return, they received RSUs equal to their surrendered vested and unvested options. For the RSUs issued in exchange for vested options, 50% will vest on August 15, 2026, and 25% will vest on each of November 15, 2026, and February 15, 2027, with full acceleration if they are terminated other than for Cause or resign for Good Reason. RSUs issued for unvested options will vest between August 15, 2026, and February 15, 2029, with an additional six months of vesting acceleration upon those same termination events.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Senior Vice President of Research and Development on a Form 4. On 11/15/2025, 1,375 shares of common stock were surrendered at a price of $3.25 per share, coded as an “F” transaction, which indicates shares withheld to cover taxes related to the vesting of restricted stock units. After this tax withholding event, the reporting person beneficially owned 39,591 shares of Artiva common stock directly. This was a routine administrative transaction tied to equity compensation rather than an open-market sale.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Chief Tech Operations Officer. On 11/15/2025, 1,899 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations tied to the vesting of restricted stock unit awards. After this tax withholding, the officer beneficially owns 78,183 shares of Artiva common stock in direct ownership. This filing is an administrative Form 4 disclosure of equity compensation and related tax settlement rather than an open-market buy or sell.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its COO, CLO, Secretary and Compliance Officer on a Form 4. On 11/15/2025, the officer had 3,055 shares of common stock withheld at a price of $3.25 per share. These shares were withheld by the company to cover income tax obligations associated with the vesting of restricted stock unit awards, rather than sold in an open-market transaction. After this tax withholding, the officer beneficially owned 148,048 shares of Artiva common stock directly.
Artiva Biotherapeutics, Inc. reported an insider equity transaction by its Chief Financial Officer, Neha Krishnamohan. On 11/15/2025, 3,490 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations related to the vesting of restricted stock unit awards. After this tax withholding, the reporting person beneficially owns 99,356 shares of Artiva common stock directly.
Artiva Biotherapeutics (ARTV) President and CEO, who is also a director, reported routine equity transactions. On 11/15/2025, 6,347 shares of common stock were withheld by the company at $3.25 per share to cover income taxes from vesting restricted stock units. On 11/17/2025, the insider sold 6,375 shares of common stock at a weighted average price of $3.376 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on July 23, 2024. Following these transactions, the insider directly beneficially owned 343,999 shares of Artiva common stock.
Artiva Biotherapeutics (ARTV) disclosed initial safety and translational data for its investigational NK cell therapy AlloNK (AB-101) combined with rituximab or obinutuzumab in autoimmune diseases. As of October 1, 2025, 32 patients across refractory RA, Sjögren’s, systemic sclerosis, SLE and lupus nephritis were treated in outpatient settings, receiving 1B or 4B cells per dose. The regimen was generally well tolerated: no AlloNK-related Grade 3+ adverse events, no discontinuations, and no cytokine release syndrome, ICANS, GvHD or hypogammaglobulinemia; one hospitalization for an unrelated skin infection.
Translational findings showed all 23 analyzed patients had non-quantifiable peripheral CD19+ B cells by Day 13, corroborated by a high-sensitivity assay, with reconstitution patterns similar to CD19 auto-CAR-T. Artiva highlighted unmet need in refractory RA and plans to share initial clinical response data from >15 RA patients in H1 2026 and conduct FDA interactions in H1 2026 on a potential pivotal trial design.